The state of Florida currently has 164 active clinical trials seeking participants for Lung Cancer research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
NCT06219174
Recruiting
The purpose of this study is to establish the safety, toxicity, and tolerability of Difluoromethylornithine (DFMO) in combination with pembrolizumab in advanced/metastatic Non-Small Cell Lung Cancer (NSCLC). Researchers also want to investigate how effective DFMO is at treating patients with advanced/ metastatic NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Non Small Cell Lung Cancer, Lung Cancer
Register for Updates
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692
Recruiting
This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Research Site, Jacksonville, Florida +2 locations
Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer
Register for Updates
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
NCT05742607
Recruiting
The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: St. Anthony's Hospital - BayCare Health System, Saint Petersburg, Florida +1 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Orlando Health Cancer Institute, Orlando, Florida +2 locations
Conditions: Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Register for Updates
Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC
NCT05363280
Recruiting
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Cleveland Clinic Florida, Weston, Florida
Conditions: Small Cell Lung Cancer
Register for Updates
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
NCT05256290
Recruiting
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: Baptist Health Miami, Miami, Florida
Conditions: Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
Register for Updates
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: AdventHealth Orlando, Orlando, Florida
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
NCT04716946
Recruiting
The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung cancer (NSCLC) than SBRT alone.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Baptist Alliance - McI, Miami, Florida
Conditions: NSCLC, Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IIIA, PD-L1 Gene Mutation
Register for Updates
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530
Recruiting
The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab given alone as further therapy in participants with resectable and borderline resectable stage IIB-IIIB NSCLC.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/04/2024
Locations: Research Site, Saint Petersburg, Florida
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128
Recruiting
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/01/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida +1 locations
Conditions: Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Register for Updates
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
NCT04746924
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Ocala Oncology Center Pl Dba Florida Cancer Affiliates Ocala, Ocala, Florida +1 locations
Conditions: Non-small Cell Lung Cancer, NSCLC
Register for Updates
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT05650879
Recruiting
The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses. A second main question is to evaluate the concentration of ELVN-002 in the blood at different doses and to see how this correlates with safety and see how the concentration of drug changes over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Advent Health Orlando, Orlando, Florida +1 locations
Conditions: HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Register for Updates